Literature DB >> 3933035

Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.

A C Altamura, S H Curry, S Montgomery, D H Wiles.   

Abstract

Seven outpatients already receiving neuroleptic drugs by depot intramuscular injections were treated in two consecutive 3-week periods with 25 mg fluphenazine doses as enanthate and decanoate esters in a double-blind crossover study. They were assessed for incidence of akinesia, involuntary movement, autonomic disturbances and drowsiness, using a rating scale, and their blood pressures and pulse rates were recorded. Blood was collected for plasma fluphenazine and plasma prolactin assay. Additionally, a handwriting test was applied. A higher incidence of unwanted drug effects occurred when plasma fluphenazine concentrations were maximal, but this was not so with prolactin concentrations. No significant blood pressure changes occurred. Small increases in pulse rate and decreases in handwriting length occurred, but these changes were not associated with high fluphenazine levels.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3933035     DOI: 10.1007/bf00431773

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  7 in total

1.  Fluphenazine enanthate and fluphenazine decanoate: a comparative study in chronic schizophrenic outpatients.

Authors:  A Keskiner; T M Itil; J M Holden
Journal:  Psychosomatics       Date:  1969 Jan-Feb       Impact factor: 2.386

2.  Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.

Authors:  D H Wiles; M G Gelder
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

3.  Unwanted effects of fluphenazine enanthate and decanoate.

Authors:  S H Curry; A C Altamura; S Montgomery
Journal:  Lancet       Date:  1979-02-10       Impact factor: 79.321

4.  Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate.

Authors:  J Kane; F Quitkin; A Rifkin; D F Klein
Journal:  Am J Psychiatry       Date:  1978-12       Impact factor: 18.112

5.  Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man.

Authors:  S H Curry; R Whelpton; P J de Schepper; S Vranckx; A A Schiff
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

6.  Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment.

Authors:  D H Wiles; T Kolakowska; A S McNeilly; B M Mandelbrote; M G Gelder
Journal:  Psychol Med       Date:  1976-08       Impact factor: 7.723

7.  Animal model for investigation of fluphenazine kinetics after administration of long-acting esters.

Authors:  A C Altamura; R Whelpton; S H Curry
Journal:  Biopharm Drug Dispos       Date:  1979 Oct-Dec       Impact factor: 1.627

  7 in total
  5 in total

Review 1.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 2.  Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.

Authors:  A Cario Altamura; Francesca Sassella; Annalisa Santini; Clauno Montresor; Sara Fumagalli; Emanuela Mundo
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.

Authors:  D H Wiles; R G McCreadie; A Whitehead
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients.

Authors:  K K Midha; E M Hawes; J W Hubbard; E D Korchinski; G McKay
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.

Authors:  Simon Zhornitsky; Emmanuel Stip
Journal:  Schizophr Res Treatment       Date:  2012-02-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.